2026 - Introduced
South Dakota H.B. 1085
  • Prohibits South Dakota insurers from denying coverage of a prescribed non-opioid medication in favor of an opioid.
  • Bars insurers from imposing stricter utilization controls or higher cost-sharing for non-opioid drugs than for clinically appropriate opioid or narcotic drugs.
2025 - Introduced
South Dakota H.B.1137
  • Ensures FDA-approved non-opioid drugs are not disadvantaged or discouraged with respect to coverage of an opioid on the state preferred drug list.
2024 - Passed
Tennessee H.B.37
  • Aligns group health insurance plans providing coverage for state employees with Medicaid non-opioid parity policy, ensuring reimbursement of all FDA-approved non-opioid drugs.
2025 - Passed
Tennessee S.B.2011/H.B.2903
  • Prevents opioids from being preferred over a non-opioid pain medication on TennCare's preferred drug list and makes a non-opioid available immediately upon FDA-approval.
  • Requires state Medicaid departments to ensure prescribers and hospitals are reimbursed for providing non-opioid medications.
  • Prohibits health insurers from denying coverage of a non-opioid prescription drug in favor of an opioid, when prescribed.
2025 - Introduced
Utah S.B. 331
  • Prohibits Medicaid and health insurers from imposing more restrictive or extensive prescription drug utilization management practices for a non-opioid drug than the least restrictive or extensive practice applicable to any opioid.
  • Requires that if Utah Department of Health and Human Services funding is available, pamphlets about opiates should include information about non-opioid drug alternatives.
2026 - Introduced
Virginia H.B. 516
  • Prohibits commercial health insurers from imposing limitations or utilization controls on coverage of a covered FDA-approved non-opioid drug that are more restrictive or less favorable to the enrollee relative to the coverage of an opioid drug for the treatment or management of pain.
2025 - Introduced
Virginia H.B.1765
  • Prohibits health insurers from imposing cost-sharing, prior authorization, step therapy, or other coverage limitations on a covered FDA-approved non-opioid drug.
2024 - Passed
Virginia H.B.699
  • Provides that the Virginia Boards of Medicine, Optometry, Dentistry, and Medicine and Nursing update regulations to require prescribers to document and discuss risks with patients.
2025 - Introduced
Virginia S.B.800
  • Ensures that no non-opioid approved by the FDA shall be disadvantaged or discouraged relative to opioids, including through prior authorization or step therapy.
2024 - Introduced
Washington H.B.1034
  • Prohibits health insurers from imposing restrictive practices that disadvantage or discourage the use of non-opioid drugs for the treatment of pain relative to opioid drugs.
2026 - Introduced
Washington S.B. 5916
  • Prohibits public and private health plans from disadvantaging non-opioid pain medications that are more restrictive or less favorable to the enrollee relative to the coverage of an opioid drug for the treatment or management of pain.
  • Requires the state to publish an educational pamphlet on non-opioid pain treatment alternatives.
2025 - Introduced
West Virginia H.B. 3070/S.B. 628
  • Prohibits West Virginia's Medicaid and commercial health insurance formularies or preferred drug lists from disadvantaging or discouraging a non-opioid drug with respect to coverage of an opioid drug, including through more restrictive coverage criteria, utilization management, or cost sharing.
  • Requires the West Virginia Bureau of Public Health develop educational materials about non-opioid alternatives for the treatment of acute pain.